Find Regorafenib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 755037-03-7, Bay 73-4506, Stivarga, 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide, Regorafenibum, Regorafenib (bay 73-4506)
Molecular Formula
C21H15ClF4N4O3
Molecular Weight
482.8  g/mol
InChI Key
FNHKPVJBJVTLMP-UHFFFAOYSA-N
FDA UNII
24T2A1DOYB

Regorafenib
Regorafenib is the anhydrous form of regorafenib, an orally bioavailable small molecule with potential antiangiogenic and antineoplastic activities. Regorafenib binds to and inhibits vascular endothelial growth factor receptors (VEGFRs) 2 and 3, and Ret, Kit, PDGFR and Raf kinases, which may result in the inhibition of tumor angiogenesis and tumor cell proliferation. VEGFRs are receptor tyrosine kinases that play important roles in tumor angiogenesis; the receptor tyrosine kinases RET, KIT, and PDGFR, and the serine/threonine-specific Raf kinase are involved in tumor cell signaling.
Regorafenib is a Kinase Inhibitor. The mechanism of action of regorafenib is as a Protein Kinase Inhibitor, and Cytochrome P450 2C9 Inhibitor.
1 2D Structure

Regorafenib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-N-methylpyridine-2-carboxamide
2.1.2 InChI
InChI=1S/C21H15ClF4N4O3/c1-27-19(31)18-10-13(6-7-28-18)33-12-3-5-17(16(23)9-12)30-20(32)29-11-2-4-15(22)14(8-11)21(24,25)26/h2-10H,1H3,(H,27,31)(H2,29,30,32)
2.1.3 InChI Key
FNHKPVJBJVTLMP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CNC(=O)C1=NC=CC(=C1)OC2=CC(=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F)F
2.2 Other Identifiers
2.2.1 UNII
24T2A1DOYB
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

2. Bay 73-4506

3. Bay-73-4506

4. Bay73-4506

5. Stivarga

2.3.2 Depositor-Supplied Synonyms

1. 755037-03-7

2. Bay 73-4506

3. Stivarga

4. 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-n-methylpicolinamide

5. Regorafenibum

6. Regorafenib (bay 73-4506)

7. Bay73-4506

8. Bay-73-4506

9. 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)-3-fluorophenoxy]-n-methylpyridine-2-carboxamide

10. Regorafenib-13c-d3

11. 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]-3-fluorophenoxy]-n-methylpyridine-2-carboxamide

12. 24t2a1doyb

13. Chembl1946170

14. Chebi:68647

15. Bay-734506

16. Stivarga (tn)

17. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

18. Regorafenib [inn]

19. Regorafenib [usan:inn]

20. Unii-24t2a1doyb

21. Fluoro-sorafenib

22. 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl}amino)-3-fluorophenoxy)-n-methylpyridine-2-carboxamide

23. Regorafenib [mi]

24. Regorafenib (usan/inn)

25. Regorafenib [vandf]

26. Regorafenib Anhydrous

27. Regorafenib [who-dd]

28. Mls006010303

29. Regorafenib Crystalline Form I

30. Schembl432230

31. Regorafenib,bay 73-4506

32. Gtpl5891

33. Dtxsid60226441

34. Ex-a058

35. Regorafenib - Bay 73-4506

36. Bcpp000352

37. Hms3654k16

38. Hms3672e15

39. Bcp02105

40. Bkd17855

41. Zinc6745272

42. Bdbm50363397

43. Mfcd16038047

44. Nsc763932

45. Nsc800865

46. S1178

47. Akos015951107

48. Am81251

49. Bay 734506

50. Bcp9000384

51. Ccg-269571

52. Cs-0170

53. Db08896

54. Nsc-763932

55. Nsc-800865

56. Sb16819

57. Ncgc00263138-01

58. Ncgc00263138-13

59. Ncgc00263138-19

60. 2-pyridinecarboxamide,4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-

61. 835621-08-4

62. Ac-25075

63. Ac-31116

64. As-16304

65. Hy-10331

66. Smr004701370

67. Ft-0674338

68. R0142

69. Sw218097-2

70. Cas:835621-07-3;regorafenib Hydrochloride

71. Regorafenib (bay73-4506,fluoro-sorafenib)

72. A25020

73. D10138

74. Ab01565826_02

75. Sr-01000941571

76. Q3891664

77. Sr-01000941571-1

78. Brd-k16730910-001-02-4

79. 2-pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-3-fluorophenoxy]-n-methyl-

80. 4-[4-({[4-chloro-3-(trifluoromethy)phenyl]carbamoyl}amino)-3-fluorophenoxy]-1-methylpyridine-2-carboxamide

81. 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic Acid Methylamide

82. Regorafenib;1-(4-chloro-3-(trifluoromethyl)phenyl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 482.8 g/mol
Molecular Formula C21H15ClF4N4O3
XLogP34.2
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count8
Rotatable Bond Count5
Exact Mass482.0768807 g/mol
Monoisotopic Mass482.0768807 g/mol
Topological Polar Surface Area92.4 Ų
Heavy Atom Count33
Formal Charge0
Complexity686
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameStivarga
PubMed HealthRegorafenib (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelStivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:Regorafenib is a monohydrate and...
Active IngredientRegorafenib
Dosage FormTablet
Routeoral; Oral
Strength40mg
Market StatusPrescription
CompanyBayer Healthcare Pharms; Bayer Hlthcare

2 of 2  
Drug NameStivarga
PubMed HealthRegorafenib (By mouth)
Drug ClassesAntineoplastic Agent
Drug LabelStivarga (regorafenib) has the chemical name 4-[4-({[4-chloro-3-(trifluoromethyl) phenyl] carbamoyl} amino)-3-fluorophenoxy]-N-methylpyridine-2-carboxamide monohydrate. Regorafenib has the following structural formula:Regorafenib is a monohydrate and...
Active IngredientRegorafenib
Dosage FormTablet
Routeoral; Oral
Strength40mg
Market StatusPrescription
CompanyBayer Healthcare Pharms; Bayer Hlthcare

4.2 Drug Indication

Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumour (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. Regorafenib is also indicated for the treatment of patients with hepatocellular carcinoma (HCC) previously treated with sorafenib.


FDA Label


Stivarga is indicated as monotherapy for the treatment of adult patients with:

- metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;

- unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;

- hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.


5 Pharmacology and Biochemistry
5.1 FDA Pharmacological Classification
5.1.1 Active Moiety
REGORAFENIB
5.1.2 FDA UNII
24T2A1DOYB
5.1.3 Pharmacological Classes
Kinase Inhibitor [EPC]; Protein Kinase Inhibitors [MoA]; Cytochrome P450 2C9 Inhibitors [MoA]
5.2 ATC Code

L01EX05


L01XE21

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


L - Antineoplastic and immunomodulating agents

L01 - Antineoplastic agents

L01E - Protein kinase inhibitors

L01EX - Other protein kinase inhibitors

L01EX05 - Regorafenib


5.3 Absorption, Distribution and Excretion

Absorption

Cmax = 2.5 g/mL; Tmax = 4 hours; AUC = 70.4 g*h/mL; Cmax, steady-state = 3.9 g/mL; AUC, steady-state = 58.3 g*h/mL; The mean relative bioavailability of tablets compared to an oral solution is 69% to 83%.


Route of Elimination

Approximately 71% of a radiolabeled dose was excreted in feces (47% as parent compound, 24% as metabolites) and 19% of the dose was excreted in urine (17% as glucuronides) within 12 days after administration of a radiolabeled oral solution at a dose of 120 mg.


Volume of Distribution

Regorafenib undergoes enterohepatic circulation with multiple plasma concentration peaks observed across the 24-hour dosing interval.


5.4 Metabolism/Metabolites

Regorafenib is metabolized by CYP3A4 and UGT1A9. The main circulating metabolites of regorafenib measured at steady-state in human plasma are M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl), both of them having similar in vitro pharmacological activity and steady-state concentrations as regorafenib. M-2 and M-5 are highly protein bound (99.8% and 99.95%, respectively). Regorafenib is an inhibitor of P-glycoprotein, while its active metabolites M-2 (N-oxide) and M-5 (N-oxide and N-desmethyl) are substrates of P-glycoprotein.


5.5 Biological Half-Life

Regorafenib, 160 mg oral dose = 28 hours (14 - 58 hours); M2 metabolite, 160 mg oral dose = 25 hours (14-32 hours); M5 metabolite, 160 mg oral dose = 51 hours (32-72 hours);


5.6 Mechanism of Action

Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis, and maintenance of the tumor microenvironment. In in vitro biochemical or cellular assays, regorafenib or its major human active metabolites M-2 and M-5 inhibited the activity of RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-alpha, PDGFR-beta, FGFR1, FGFR2, TIE2, DDR2, TrkA, Eph2A, RAF-1, BRAF, BRAFV600E , SAPK2, PTK5, and Abl at concentrations of regorafenib that have been achieved clinically. In in vivo models, regorafenib demonstrated anti-angiogenic activity in a rat tumor model, and inhibition of tumor growth as well as anti-metastatic activity in several mouse xenograft models including some for human colorectal carcinoma.


Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Coating Systems & Additives

read-more
read-more

Direct Compression

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Lubricants & Glidants

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Granulation

read-more
read-more

Co-Processed Excipients

read-more
read-more

Solubilizers

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Parenteral

read-more
read-more

Emulsifying Agents

read-more
read-more

Taste Masking

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

API Stability Enhancers

read-more
read-more

Coloring Agents

read-more
read-more

Topical

read-more
read-more

Rheology Modifiers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Regorafenib Manufacturers

A Regorafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Regorafenib, including repackagers and relabelers. The FDA regulates Regorafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Regorafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Regorafenib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.

Regorafenib Suppliers

A Regorafenib supplier is an individual or a company that provides Regorafenib active pharmaceutical ingredient (API) or Regorafenib finished formulations upon request. The Regorafenib suppliers may include Regorafenib API manufacturers, exporters, distributors and traders.

click here to find a list of Regorafenib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Regorafenib USDMF

A Regorafenib DMF (Drug Master File) is a document detailing the whole manufacturing process of Regorafenib active pharmaceutical ingredient (API) in detail. Different forms of Regorafenib DMFs exist exist since differing nations have different regulations, such as Regorafenib USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Regorafenib DMF submitted to regulatory agencies in the US is known as a USDMF. Regorafenib USDMF includes data on Regorafenib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Regorafenib USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Regorafenib suppliers with USDMF on PharmaCompass.

Regorafenib KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Regorafenib Drug Master File in Korea (Regorafenib KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Regorafenib. The MFDS reviews the Regorafenib KDMF as part of the drug registration process and uses the information provided in the Regorafenib KDMF to evaluate the safety and efficacy of the drug.

After submitting a Regorafenib KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Regorafenib API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Regorafenib suppliers with KDMF on PharmaCompass.

Regorafenib WC

A Regorafenib written confirmation (Regorafenib WC) is an official document issued by a regulatory agency to a Regorafenib manufacturer, verifying that the manufacturing facility of a Regorafenib active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Regorafenib APIs or Regorafenib finished pharmaceutical products to another nation, regulatory agencies frequently require a Regorafenib WC (written confirmation) as part of the regulatory process.

click here to find a list of Regorafenib suppliers with Written Confirmation (WC) on PharmaCompass.

Regorafenib NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Regorafenib as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Regorafenib API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Regorafenib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Regorafenib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Regorafenib NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Regorafenib suppliers with NDC on PharmaCompass.

Regorafenib GMP

Regorafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Regorafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Regorafenib GMP manufacturer or Regorafenib GMP API supplier for your needs.

Regorafenib CoA

A Regorafenib CoA (Certificate of Analysis) is a formal document that attests to Regorafenib's compliance with Regorafenib specifications and serves as a tool for batch-level quality control.

Regorafenib CoA mostly includes findings from lab analyses of a specific batch. For each Regorafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Regorafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Regorafenib EP), Regorafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Regorafenib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty